CN108576764A - 一种解酒保肝复配甜味剂及其制备方法 - Google Patents
一种解酒保肝复配甜味剂及其制备方法 Download PDFInfo
- Publication number
- CN108576764A CN108576764A CN201810228667.5A CN201810228667A CN108576764A CN 108576764 A CN108576764 A CN 108576764A CN 201810228667 A CN201810228667 A CN 201810228667A CN 108576764 A CN108576764 A CN 108576764A
- Authority
- CN
- China
- Prior art keywords
- acid
- parts
- liver
- antialcoholic liver
- composite sweetener
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003599 food sweetener Nutrition 0.000 title claims abstract description 46
- 239000003765 sweetening agent Substances 0.000 title claims abstract description 46
- 230000002075 anti-alcohol Effects 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title description 29
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 20
- HLDYLAJAWSKPFZ-QDPIGISRSA-N glycyrrhetic acid 3-O-glucuronide Chemical compound O([C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HLDYLAJAWSKPFZ-QDPIGISRSA-N 0.000 claims abstract description 20
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 20
- 239000002131 composite material Substances 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 17
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 16
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 16
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000000945 filler Substances 0.000 claims abstract description 12
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011122 softwood Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 17
- 206010067125 Liver injury Diseases 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 16
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 231100000753 hepatic injury Toxicity 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 240000006394 Sorghum bicolor Species 0.000 description 5
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/34—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种解酒保肝复合甜味剂及其制备方法,复合甜味剂包含下述重量份配比的组分制成的药剂:1‑2份的甘草酸、3‑5份的单葡萄糖醛酸甘草次酸、1‑2份的葡萄糖醛酸、1‑3份的酸味剂及10‑50份的填充剂。本发明的复合甜味剂的冲剂制备方法简单,方便贮存运输。本发明的复合甜味剂安全可靠,食用方便,具有解酒醒酒、预防和治疗因酒精引起的急性肝损伤的疗效。
Description
技术领域
本发明涉及食品、保健领域,尤其涉及一种解酒保肝复配甜味剂及其制备方法。
背景技术
酒早已成为社会活动不可缺少的工具,但是如果饮酒过量,使乙醇在体内的吸收率大于氧化代谢率,较多的乙醇经血液循环进入人体大脑内,作用于中枢神经***;同时,乙醇代谢会产生大量的自由基O-2、OH-、H2O2、C2H5O-,形成自由基反应,刺激神经***,导致自律神经平衡失调引起的心跳加速,血液中水分与电解质平衡失调,造成头痛、晕眩、局部皮肤过敏,肠胃不适等症状。
人体内大概90%酒精在肝脏中代谢,因此,增强肝脏内相关乙醇代谢酶如乙醇脱氢酶(ADH)、乙醛脱氢酶(ALDH)等活性是醒酒制品主要的药理作用依据。乙醇脱氢酶(ADH)作为人体内酒精代谢的重要酶,具有立体专一性,以NAD+为辅酶,将乙醇氧化为乙醛,而乙醛脱氢酶则将氧化乙醛中的两个氢原子,使乙醛转化为乙酸,最终进入三羧酸循环分解为二氧化碳和水。乙醇在人体内的代谢速率是有限度的,如果饮酒过量,酒精就会在体内器官,特别是在肝脏和大脑中积蓄,积蓄至一定程度就会出现酒精中毒症状。
醒酒机理研究主要包括两大方面:一方面是通过直接加快体内的乙醇氧化代谢来促进醒酒,如增强ADH和ALDH酶活性,降低血醇浓度,减轻其对机体的伤害;另一方面是通过增强清除自由基能力促进酒精氧化代谢正方向进行,如增强超氧化物歧化酶 (SOD)、谷胱甘肽转硫酶(GST),过氧化氢酶活性等,快速清除自由基,减轻其对肝脏的损伤。
目前,市场上的醒酒产品多由中草药按照古方糅合制成;现有的解酒保肝相关的专利中大多数组成原料也都是葛根、茯苓、枳椇子、甘草等中草药,这些中草药对于长期饮酒的人不宜长期服用,可能存在副作用。
发明内容
发明目的:本发明提供了一种解酒保肝用的复配甜味剂替代现有的中药复方解酒制剂。本发明还提供了该甜味剂的制备方法。
技术方案:本发明所述的一种解酒保肝复合甜味剂,它是包含下述重量份配比的组分制成的药剂:1-2份的甘草酸、3-5份的单葡萄糖醛酸甘草次酸、1-2份的葡萄糖醛酸、1-3份的酸味剂及10-50份的填充剂。
上述单葡萄糖醛酸甘草次酸(GAMG)是以水溶性甘草酸盐为底物,经过β-D葡萄糖内切糖苷酶水解,转化液经萃取、结晶获得,其结构式为:
葡萄糖醛酸是一种肝脏解毒剂和免疫功能调节剂,常规的保肝护肝辅助用药类非处方药药品。其能与含有羟基、羧基、巯基的有毒物质结合,形成无毒或低毒的葡萄糖醛酸结合物由尿排出,起到保肝解毒的作用。
在收集的429首解酒方中,显示葛根、茯苓、甘草等药物为解酒方高频药物。甘草能促进胃部粘液形成和分泌,抑制胃部乙醇吸收,具有增强肝脏解毒、保护肝损伤的功能。甘草酸是甘草根部提取物中的重要成分之一,具有抗炎、抗溃疡、抗过敏、免疫调节、抗病毒、抗癌和保肝等多种生物活性。此外,与其他药物联用,可起增效作用。
而天然存在的甘草酸,在特异性酶生物转化的条件下可以转化为单葡萄糖醛酸甘草次酸(GAMG),其解酒活性强,肝脏靶向性高,副作用小,安全性强。
研究发现,甘草酸能稳定肝细胞膜结构,降低血液中谷丙转氨酶(ALT)、谷草转氨酶(AST)活性,增强肝组织SOD活性,降低肝组织丙二醛(MDA)含量。
上述的解酒保肝复合甜味剂,其中各组分的重量份配比为:1-2份的甘草酸、4-5份的单葡萄糖醛酸甘草次酸、1-2份的葡萄糖醛酸、2-3份的酸味剂及10-50份的填充剂。
进一步地,各组分的重量份配比为:甘草酸、单葡萄糖醛酸甘草次酸、葡萄糖醛酸和酸味剂的比值为2:5:1:1,各组分在该比例范围内,具有更好的解酒保肝的效果。
上述酸味剂选自柠檬酸、柠檬酸钠及苹果酸中的一种或多种。
上述填充剂为赤藓糖醇、山梨糖醇和木糖醇的一种或几种。
上述的解酒保肝复合甜味剂可以制备成液剂或冲剂。
为了更好的储存和运输,解酒保肝复合甜味剂优选地剂型为冲剂。
解酒保肝复合甜味剂冲剂的制备方法如下:
(1)将甘草酸、单葡萄糖醛酸甘草次酸、葡萄糖醛酸和酸味剂和填充剂按比例混合,在3000-8000rpm转速下粉碎,混合均匀,过60-100目筛;
(2)加入适量的润湿剂混匀制成软材;
(3)用摇摆式颗粒机制湿颗粒,在40-50℃温度下干燥至恒重,得到冲剂。
上述的润湿剂可以为常用的润湿剂即可,不限润湿剂的种类,如可采用氧化镁作为基材。
有益效果:(1)甘草酸、单葡萄糖醛酸甘草次酸和葡萄糖醛酸都是天然活性成分,符合国家食品添加剂使用标准,安全可靠,无毒副作用;(2)制成的解酒保肝复配甜味剂,可独立小包装,食用方便,且解酒保肝复配甜味剂易于溶于水和乙醇溶液中;(3) 葡萄糖醛酸、甘草酸和单葡萄糖醛酸具有协同增效作用,可以增强乙醇脱氢酶和乙醛脱氢酶等代谢酶活性,同时可以快速清除乙醇代谢过程中产生的大量自由基,降低酒精对肝细胞的损伤,具有解酒保肝的功效。
具体实施方式
一、原料来源
单葡萄糖醛酸甘草次酸(GAMG):亿利耐雀生物技术有限公司;本发明所用的其它原料均为市售所得。
二、样品制备
实施例1:解酒保肝复配甜味剂由1g甘草酸、3g单葡萄糖醛酸甘草次酸(GAMG)、 1g葡萄糖醛酸、1g苹果酸和50g赤藓糖醇组成。
实施例2:解酒保肝复配甜味剂由2g甘草酸、5g单葡萄糖醛酸甘草次酸(GAMG)、 2g葡萄糖醛酸、3g苹果酸、20g赤藓糖醇和15g山梨糖醇组成。
实施例3:解酒保肝复配甜味剂由1.5g甘草酸、4g单葡萄糖醛酸甘草次酸(GAMG)、1.5g葡萄糖醛酸、1g苹果酸、1g苹果酸钠、20g赤藓糖醇、10g山梨糖醇和10g木糖醇组成。
实施例4:解酒保肝复配甜味剂按以下重量份的组分混合:2份甘草酸、5份单葡萄糖醛酸甘草次酸(GAMG)、1份葡萄糖醛酸、0.5份柠檬酸、0.25份柠檬酸钠、0.25份苹果酸、20份赤藓糖醇、15份山梨糖醇和15份木糖醇,将实施例4制备的样品做以下动物实验。
对比例1:无葡萄糖醛酸,其余同实施例4。
对比例2:无甘草酸,其余同实施例4。
对比例3:无葡萄糖醛酸和甘草酸,其余同实施例4。
三、动物实验
3.1实验材料
3.1.1实验样品
取实施例4制备的样品作为实验样品,将对比例1-3制备的样品作为本产品的对比样品,海王金樽片作为现有技术对照组,蒸馏水作为空白对照组。
3.1.2受试动物
江苏种小鼠,SPF级,由江苏省实验动物中心提供,雄性,体重18-20g。
3.1.3药物与试剂
ALT试剂盒、AST试剂盒、MDA试剂盒均由南京建成生物工程研究所提供;56°红星二锅头,北京红星二锅头酒厂生产。
3.2实验方法
2.2.1小鼠攀附实验
取60只雄性小鼠,随机分为6组,每组10只,分为解酒保肝复配甜味剂组、对比例1组、对比例2组、对比例3组、海王金樽组、和空白组(蒸馏水),实验前禁食12h。给药浓度为30mg/kg,各组灌胃30min后,分别灌胃红星二锅头15mL/kg,随即将小鼠放在垂直金属网上,记录各小鼠在网上的攀附时间。
3.2.2小鼠反正实验
取60只雄性小鼠,随机分为6组,每组10只,分为解酒保肝复配甜味剂组、对比例1组、对比例2组、对比例3组、海王金樽组、和空白组(蒸馏水),实验前禁食12h。给药浓度为30mg/kg,各组灌胃30min后,分别灌胃红星二锅头15mL/kg,随即记录各小鼠翻正反应消失时间(耐受时间)和持续消失时间。
3.2.3小鼠醉酒睡眠实验
取60只雄性小鼠,随机分为6组,每组10只,分为解酒保肝复配甜味剂组、对比例1组、对比例2组、对比例3组、海王金樽组、和空白组(蒸馏水),实验前禁食12h。给药浓度为30mg/kg,各组灌胃30min后,分别灌胃红星二锅头15mL/kg,随即观察小鼠活动情况。以小白鼠爬行不稳、后腹拖地、闭眼懒动为睡眠(醉酒)指标,以行动自如、四肢灵活、精神恢复为苏醒(醒酒)指标,记录小鼠入眠时间和苏醒时间,计算睡眠耐受时间(从灌酒至入睡的时间)及持续时间(从入睡到苏醒的时间)。
3.2.4对酒精性肝损伤的影响
取70只雄性小鼠,随机分为7组,每组10只,解酒保肝复配甜味剂组、对比例1 组、对比例2组、对比例3组、海王金樽组、和空白组(蒸馏水)和正常组。每天给予正常饲料和饮水,给药浓度为30mg/kg,各组灌胃30min后用红星二锅头按每天15mL/kg 剂量连续灌解酒保肝复配甜味剂组、对比例1组、对比例2组、对比例3组、海王金樽组、空白组2周,建立小鼠急性酒精性肝损伤模型。末次给酒12h,眼球取血,血液在室温放置30min。待血液凝固后,4℃,3000r/min离心15min,取上清液,按照试剂盒提供的方法检测血清ALT和AST。称取小鼠肝脏2g,剪碎,用生理盐水20mL制成10%的肝匀浆液,于3000r/min离心10min,取上清液备用,按照试剂盒提供方法检测肝组织SOD,MDA。
3.3实验结果
3.3.1对小鼠攀附能力的影响
小鼠攀附实验结果如表1所示,与空白组比较,解酒保肝复配甜味剂组可显著延长小鼠攀附时间。
表1解酒保肝复配甜味剂对小鼠攀附能力的影响
组别 | 攀附时间(s) |
空白组 | 180.23 |
海王金樽组 | 250.58 |
解酒保肝复配甜味剂组 | 289.29 |
对比例1 | 247.54 |
对比例2 | 254.72 |
对比例3 | 232.12 |
3.3.2对小鼠翻正反射恢复时间的影响
小鼠翻正实验结果如表2所示,与空白组比较,解酒保肝复配甜味剂组可显著延长小鼠翻正反射消失时间和缩短翻正反射消失持续时间。
表2解酒保肝复配甜味剂对小鼠翻正反射恢复时间的影响
组别 | 消失时间(min) | 消失持续时间(min) |
空白组 | 26.28 | 207.16 |
解酒保肝复配甜味剂组 | 35.65 | 142.81 |
海王金樽组 | 31.61 | 159.27 |
对比例1 | 31.62 | 156.41 |
对比例2 | 32.19 | 153.60 |
对比例3 | 29.41 | 177.33 |
3.3.3对小鼠醉酒睡眠时间的影响
小鼠醉酒睡眠实验结果如表3所示,与空白组比较,解酒保肝复配甜味剂组可显著延长小鼠睡眠潜伏时间和缩短睡眠持续时间。
表3解酒保肝复配甜味剂对小鼠醉酒睡眠时间的影响
组别 | 睡眠潜伏时间(min) | 睡眠持续时间(min) |
空白组 | 24.57 | 250.46 |
解酒保肝复配甜味剂组 | 29.94 | 172.32 |
海王金樽组 | 28.29 | 195.68 |
对比例1 | 28.55 | 180.83 |
对比例2 | 27.25 | 186.09 |
对比例3 | 26.25 | 198.21 |
3.3.4对小鼠酒精性肝损伤的影响
对酒精性肝损伤影响的实验结果如表4所示,与正常组比较,空白组小鼠ALT和AST水平显著升高,SOD含量显著降低,MDA含量显著升高,表明酒精对小鼠肝损伤显著,急性酒精性肝损伤模型造模成功。与空白组比较,解酒保肝复配甜味剂组能显著降低小鼠血清中ALT和AST含量,显著升高小鼠肝脏的SOD含量和降低小鼠肝脏的 MDA含量,表明解酒保肝复配甜味剂组能够减轻小鼠因酒精引起的急性肝损伤。
表4解酒保肝复配甜味剂对小鼠酒精性肝损伤的影响
上述实验结果表明,本发明提供的解酒保肝复配甜味剂能够有效起到解酒作用、缓解醉酒的程度并减轻因酒精引起的急性肝损伤。
四、产品的贮存
为了更好的贮存产品,将甘草酸、单葡萄糖醛酸甘草次酸、葡萄糖醛酸、酸味剂和填充剂按比例混合,在8000rpm转速下粉碎,得到的混合物过60目筛,随后,与填充剂的质量比为10:1的数量,添加填充剂氧化镁混合,用摇摆式颗粒机制湿颗粒制粒,在 50℃温度下干燥,得到冲剂,方便产品的运输和贮存。
Claims (8)
1.一种解酒保肝复合甜味剂,其特征在,它是包含下述重量份配比的组分制成的药剂:1-2份的甘草酸、3-5份的单葡萄糖醛酸甘草次酸、1-2份的葡萄糖醛酸、1-3份的酸味剂及10-50份的填充剂。
2.根据权利要求1所述的解酒保肝复合甜味剂,其特征在于,其中各组分的重量份配比为:1-2份的甘草酸、4-5份的单葡萄糖醛酸甘草次酸、1-2份的葡萄糖醛酸、2-3份的酸味剂及10-50份的填充剂。
3.根据权利要求2所述的解酒保肝复合甜味剂,其特征在于,其中各组分的重量份配比为:甘草酸、单葡萄糖醛酸甘草次酸、葡萄糖醛酸和酸味剂的比值为2:5:1:1。
4.根据权利要求1所述的解酒保肝复合甜味剂,其特征在于,所述酸味剂选自柠檬酸、柠檬酸钠及苹果酸中的一种或多种。
5.根据权利要求1所述的解酒保肝复合甜味剂,其特征在于,所述填充剂为赤藓糖醇、山梨糖醇和木糖醇的一种或几种。
6.根据权利要求1-5所述的任一解酒保肝复合甜味剂,其特征在于,所述的药剂为液剂或冲剂。
7.根据权利要求6所述的解酒保肝复合甜味剂,其特征在于,所述的药剂为冲剂。
8.根据权利要求7所述的解酒保肝复合甜味剂的制备方法,其特征在于,包括以下步骤:
(1)将甘草酸、单葡萄糖醛酸甘草次酸、葡萄糖醛酸、酸味剂和填充剂按比例混合,在3000-8000rpm转速下粉碎,混合均匀,过60-100目筛;
(2)加入适量的润湿剂混匀制成软材;
(4)用摇摆式颗粒机制湿颗粒,在40-50℃温度下干燥至恒重,得到冲剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810228667.5A CN108576764A (zh) | 2018-03-20 | 2018-03-20 | 一种解酒保肝复配甜味剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810228667.5A CN108576764A (zh) | 2018-03-20 | 2018-03-20 | 一种解酒保肝复配甜味剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108576764A true CN108576764A (zh) | 2018-09-28 |
Family
ID=63626797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810228667.5A Pending CN108576764A (zh) | 2018-03-20 | 2018-03-20 | 一种解酒保肝复配甜味剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108576764A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114304587A (zh) * | 2021-12-29 | 2022-04-12 | 亿利耐雀生物科技有限公司 | 一种含有阿洛酮糖的复配甜味剂及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101312661A (zh) * | 2005-11-23 | 2008-11-26 | 可口可乐公司 | 具有改良时间变化形廓及/或风味形廓的天然高效甜味剂组成物与其调和方法和用途 |
CN106343123A (zh) * | 2016-08-25 | 2017-01-25 | 江苏海智生物医药有限公司 | 一种保健巧克力 |
CN106591071A (zh) * | 2016-12-23 | 2017-04-26 | 江苏耐雀生物工程技术有限公司 | 一种保健白酒及其制备方法 |
CN106636290A (zh) * | 2017-02-03 | 2017-05-10 | 江南大学 | 一种发酵生产单葡萄糖醛酸甘草次酸的方法和应用 |
CN107156772A (zh) * | 2017-06-01 | 2017-09-15 | 亿利耐雀生物科技有限公司 | 一种新型复配甜味剂及其制备方法 |
CN107286218A (zh) * | 2017-06-01 | 2017-10-24 | 亿利耐雀生物科技有限公司 | 一种新的齐墩果烷型三萜皂苷衍生物的制备方法 |
CN107412665A (zh) * | 2017-09-07 | 2017-12-01 | 张钰 | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 |
-
2018
- 2018-03-20 CN CN201810228667.5A patent/CN108576764A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101312661A (zh) * | 2005-11-23 | 2008-11-26 | 可口可乐公司 | 具有改良时间变化形廓及/或风味形廓的天然高效甜味剂组成物与其调和方法和用途 |
CN106343123A (zh) * | 2016-08-25 | 2017-01-25 | 江苏海智生物医药有限公司 | 一种保健巧克力 |
CN106591071A (zh) * | 2016-12-23 | 2017-04-26 | 江苏耐雀生物工程技术有限公司 | 一种保健白酒及其制备方法 |
CN106636290A (zh) * | 2017-02-03 | 2017-05-10 | 江南大学 | 一种发酵生产单葡萄糖醛酸甘草次酸的方法和应用 |
CN107156772A (zh) * | 2017-06-01 | 2017-09-15 | 亿利耐雀生物科技有限公司 | 一种新型复配甜味剂及其制备方法 |
CN107286218A (zh) * | 2017-06-01 | 2017-10-24 | 亿利耐雀生物科技有限公司 | 一种新的齐墩果烷型三萜皂苷衍生物的制备方法 |
CN107412665A (zh) * | 2017-09-07 | 2017-12-01 | 张钰 | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
吴世敏: "《简明精细化工大辞典》", 30 June 1999, 辽宁科学技术出版社 * |
张媛: "甘草酸治疗酒精性肝病的机制研究进展", 《中西医结合肝病杂志》 * |
陈彦: "筛选中药提取物及联合葡醛内酯醒酒活性和机理研究", 《安徽大学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114304587A (zh) * | 2021-12-29 | 2022-04-12 | 亿利耐雀生物科技有限公司 | 一种含有阿洛酮糖的复配甜味剂及其制备方法 |
CN114304587B (zh) * | 2021-12-29 | 2024-05-03 | 亿利耐雀生物科技有限公司 | 一种含有阿洛酮糖的复配甜味剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
CN108434231A (zh) | 一种抗醉解酒的药食同源中药组合物及其制备方法 | |
CN107050148B (zh) | 一种解酒保肝中药组合物及其制备方法 | |
CN102132869B (zh) | 一种具解酒防醉作用保健用品 | |
WO2020052074A1 (zh) | 一种提高肝脏排毒、解酒护肝的提取物及其制备方法 | |
CN104666996A (zh) | 提神抗疲劳的中药组合物及其制备方法与应用 | |
CN107951935A (zh) | 一种葛根枳椇子破壁组合物及其制备方法和应用 | |
CN103343083A (zh) | 一种护肝解酒果醋及其制备方法 | |
WO2008014256A2 (en) | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers | |
CN106563099A (zh) | 一种解酒护肝口服液 | |
CN105362384A (zh) | 一种解酒醒酒的中药组合物及其应用 | |
CN101284128A (zh) | 一种解酒防醉药物及其制备方法 | |
CN102205013B (zh) | 白附子的中药炮制方法 | |
CN109480011A (zh) | 一种具有养胃护肝功能的解酒茶及其制备方法 | |
CN109170900A (zh) | 一种具有护肝解酒保健作用的食品组合物 | |
CN106822622A (zh) | 一种解酒护肝口服组合物及其制备方法 | |
CN108576764A (zh) | 一种解酒保肝复配甜味剂及其制备方法 | |
CN108143974A (zh) | 解酒护肝丸 | |
CN108497118A (zh) | 一种解酒保健茶及其制备方法 | |
CN101461836A (zh) | 一种新型具有解酒保肝护胃功效的浓缩饮液及其制法 | |
CN101244084B (zh) | 一种珍珠贝肉解酒剂及其制备方法 | |
CN108770971A (zh) | 一种解酒护肝巧克力及其制备方法 | |
CN106727902B (zh) | 含冬虫夏草的解酒护肝中药组合物及其应用 | |
CN110856549A (zh) | 一种无糖功能食品及其制备方法 | |
CN109043035A (zh) | 一种具有解酒护眼功效的速溶沙棘果茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |
|
RJ01 | Rejection of invention patent application after publication |